Concepedia

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

Christian P. Larsen, Josep M. Grinyó, José Osmar Medina Pestana, Yves Vanrenterghem, Flavio Vincenti, Barbara Breshahan, Josep M. Campistol, Sander Florman, María del Carmen Rial, Nassim Kamar,

Transplantation · 2010 · 171 citations · 21 references

DOI

Abstract

At 2 years, belatacept-based regimens sustained better renal function, similar patient/graft survival, and an improved cardiovascular/metabolic risk profile versus CsA; outcomes that were maintained in EBV (+) patients. No new safety signals emerged.

References

21

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Andrew S. Levey, Juan Bosch, Julia B. Lewis et al. · Annals of Internal Medicine · 1999 · 15K citations

Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era

Herwig‐Ulf Meier‐Kriesche, Jesse D. Schold, Titte R. Srinivas et al. · American Journal of Transplantation · 2004 · 1.3K citations

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al. · American Journal of Transplantation · 2010 · 931 citations

, , +13

Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

Antoine Dürrbach, JO Medina Pestana, Thomas C. Pearson et al. · American Journal of Transplantation · 2010 · 555 citations · Full text

, , +15

Hypertension after kidney transplantation

Bertram L. Kasiske, Shakeel Anjum, Rajiv Shah et al. · American Journal of Kidney Diseases · 2004 · 414 citations

, , +8